Metaprotereol Sulfate Inhalation Solution, 5%

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved March 1997

Specific Treatments:

bronchial asthma and reversible bronchospasm

Find Related Trials for The Following Conditions

General Information

Metaprotereol Sulfate Inhalation Solution, 5% has been approved for the treatment of bronchial asthma and reversible bronchospasm. The product is also indicated for the treatment of acute asthmatic attacks in children over the age of six. Metaprotereol Sulfate Inhalation Solution, 5% was found to be therapeutically bioequivalent to the listed drug, Alupentr Inhalation Solution, 5% marketed by Boehringer Ingelheim Pharmaceuticals, Inc.